Corporate Banner
Satellite Banner
Technology Networks Header
Wednesday, January 28, 2015
Technology Networks
 
Register | Sign in
Home Page>Posters

  Posters

Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
Daniel Brown (1), Niklas Larsson (2), Ola Fjellström (3), Anders Johansson (3), Sara Lundqvist (2), Johan Brengdahl (2), and Richard J. Isaacs (1)

We describe the application of back-scattering interferometry (BSI) to the characterization of small molecule ligand binding to human GPR39 (a GPCR targeted for type-2 diabetes therapy) overexpressed in crude membrane fractions in free solution, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffolds.

Mixtures Analysis of Complex Mixtures
Michael Bernstein; Carlos Cobas; Santi Domínguez; Manuel Pérez; Agustín Barba

We describe an NMR method to quantify mixture components in wine, edible oils, etc. The method is fully customizable, and amenable to high throughput operation.

Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
Daniel Brown (1), Niklas Larsson (2), Ola Fjellström (3), Anders Johansson (3), Sara Lundqvist (2), Johan Brengdahl (2), and Richard J. Isaacs (1)

We describe the application of back-scattering interferometry (BSI) to the characterization of small molecule ligand binding to human GPR39 (a GPCR targeted for type-2 diabetes therapy) overexpressed in crude membrane fractions in free solution, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffolds

MAB Discovery Technology: A Smart Way to Highly Diverse and Functional Therapeutic Antibodies
Hans-Willi Krell

MAB Discovery GmbH developped a highly integrated process which provides diverse antibodies by starting with a high number of B cells and filtering the relevant antibodies by an early-on functional screening.

PRESEPSIN, A SOLUBLE CD14-SUBTYPE, A POSSIBLE NEW BIOMARKER INCREASES IN SEPTIC PATIENTS’ PLASMA FROM PEDIATRIC DEPARTMENT.
Hayato YAMAGUCHI1), Satoshi KIMURA1), Seiji FUKUOKA1), Emiko NAKAMA1), Hideyasu OTO2), Makoto INOUE2), Takashi SOGA2), Shigetaka KITAZAWA2), Yoh UMEDA2)

Increased plasma concentration of soluble CD14-subtype (presepsin) was observed in pediatric patients with bacteremia. Presepsin could be a possible biomarker of sepsis in pediatric patients, however, their reference interval in children could be lower than that of adults. More studies with larger number of samples are required to confirm the result.

A Novel Approach Toward Microfluidic Drug Metabolite Synthesis – Electrosynthetic Methodology Simulating Cytochrome (CYP450) Oxidation
Romain Stalder, Gregory P. Roth and Philip Podmore

A novel microfluidic technology and electrochemical synthesis method is demonstrated for the efficient generation of known drug metabolites. These metabolites are typically generated on first pass hepatic oxidation in vivo. The FLUX Module, a new microfluidic electrochemical cell manufactured by Syrris Ltd., has been employed to generate the metabolites of five commercial drugs: Tolbutamide, Chlorpromazine, Diclofenac, Primidone and Albendazole.

Exploring the Therapeutic Potential of a Peptide Derived from a Poxviral Immune Evasion Protein
Dylan Lawless

•9R-VIPER is an effective at TLR4 and TLR2 signal inhibition than VIPER.
•The structure of 9R-VIPER and the mutant peptide L6AE10A were investigated by NMR.
•Important structural information was uncovered and an explanation was found for the loss
of activity when important residues are changed.

On-chip quantification of miRNA using digital droplet PCR
Q. Cai1, R.S. Wiederkehr1, B. Jones1, B. Majeed1, T. Stakenborg1, P. Fiorini1, L. Lagae1, M Tsukuda2, T. Matsuno2, I. Yamashita2

miRNAs have a great potential in diagnostics. Hence, automated profiling of miRNAs are of great interest. In-house technology show that it is possible to implement a multiplexing assay for miRNAs on a microfluidic chip using digital droplet PCR.

High-throughput analysis of protein formulations by DLS
Sophia Kenrick and Daniel Some

High-throughput analysis of protein formulations by Dynamic Light Scattering (DLS): thermal stability, colloidal stability and a thermal anomaly in the colloidal stability parameter D1

<< 1 2 3 4 5 6 7 >>
Showing Results 21 - 30 of 167
Scientific News
Novogen Announces Important Discovery in Regenerative Medicine Program
A key proof-of-concept step to develop drugs capable of stimulating the function of brain tissue stem cells.
Stanford Chemists Take Step Toward Solving Mystery of How Enzymes Work
Steven Boxer and his students have found that the electrostatic field within an enzyme accounts for the lion's share of its success.
New Class of Synthetic Molecules Mimics Antibodies
A Yale University lab has crafted the first synthetic molecules that have both the targeting and response functions of antibodies.
The Hunt for Botanicals
Herbal medicine can be a double-edged sword and should be more rigorously investigated for both its beneficial and harmful effects, say researchers writing in a special supplement of Science.
Novel Agent Decreases Neuropathic Pain in Patients with Type 2 Diabetes
Promising profile of disease modification and pain reduction leads to proof of concept trials.
Barrier-Breaking Drug May Lead to Spinal Cord Injury Treatments
NIH-funded scientists take first step towards developing promising new drug.
Two Drugs are No More Effective Than One to Treat Common Kidney Disease
NIH study finds limited kidney benefit from more rigorous blood pressure treatment.
Antibiotic Resistance Threatens Future of Modern Medicine
Overuse and misuse of antibiotics, one of the key contributors to antimicrobial resistance (AMR).
Computer Model Sets New Precedent in Drug Discovery
New computational model can precisely simulate, predict therapeutic protein behaviors to help zero in on ideal drug design candidates.
New Drug for Common Liver Disease Improves Liver Health
An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the NIH.
Skyscraper Banner
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn